Literature DB >> 19717886

A radiobiological analysis of the effect of 3D versus 4D image-based planning in lung cancer radiotherapy.

Teboh Roland1, Panayiotis Mavroidis, Alonso Gutierrez, Virginia Goytia, Niko Papanikolaou.   

Abstract

Dose distributions generated on a static anatomy may differ significantly from those delivered to temporally varying anatomy such as for abdominal and thoracic tumors, due largely in part to the unavoidable organ motion and deformation effects stemming from respiration. In this work, the degree of such variation for three treatment techniques, namely static conventional, gating and target tracking radiotherapy, was investigated. The actual delivered dose was approximated by planning all the phases of a 4DCT image set. Data from six (n = 6) previously treated lung cancer patients were used for this study with tumor motion ranging from 2 to 10 mm. Complete radiobiological analyses were performed to assess the clinical significance of the observed discrepancies between the 3D and 4DCT image-based dose distributions. Using the complication-free tumor control probability (P+) objective, we observed small differences in P+ between the 3D and 4DCT image-based plans (<2.0% difference on average) for the gating and static conventional regimens and higher differences in P+ (4.0% on average) for the tracking regimen. Furthermore, we observed, as a general trend, that the 3D plan underestimated the P+ values. While it is not possible to draw any general conclusions from a small patient cohort, our results suggest that there exists a patient population in which 4D planning does not provide any additional benefits beyond that afforded by 3D planning for static conventional or gated radiotherapy. This statement is consistent with previous studies based on physical dosimetric evaluations only. The higher differences observed with the tracking technique suggest that individual patient plans should be evaluated on a case-by-case basis to assess if 3D or 4D imaging is appropriate for the tracking technique.

Entities:  

Mesh:

Year:  2009        PMID: 19717886     DOI: 10.1088/0031-9155/54/18/011

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

1.  Tradeoffs for assuming rigid target motion in Mlc-based real time target tracking radiotherapy: a dosimetric and radiobiological analysis.

Authors:  T Roland; C Shi; Y Liu; R Crownover; P Mavroidis; N Papanikolaou
Journal:  Technol Cancer Res Treat       Date:  2010-04

2.  Incorporating system latency associated with real-time target tracking radiotherapy in the dose prediction step.

Authors:  Teboh Roland; Panayiotis Mavroidis; Chengyu Shi; Nikos Papanikolaou
Journal:  Phys Med Biol       Date:  2010-04-19       Impact factor: 3.609

3.  Impact of Intra-Fractional Motion on Dose Distributions in Lung IMRT.

Authors:  Mikhail A Chetvertkov; Oleg N Vassiliev; Jinzhong Yang; He C Wang; Amy Y Liu; Zhongxing Liao; Radhe Mohan
Journal:  J Radiother Pract       Date:  2020-01-09

4.  Visualisation of respiratory tumour motion and co-moving isodose lines in the context of respiratory gating, IMRT and flattening-filter-free beams.

Authors:  Yvonne Dzierma; Frank G Nuesken; Jochen Fleckenstein; Stephanie Kremp; Norbert P Licht; Christian Ruebe
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

5.  Correlation of primary middle and distal esophageal cancers motion with surrounding tissues using four-dimensional computed tomography.

Authors:  Wei Wang; Jianbin Li; Yingjie Zhang; Qian Shao; Min Xu; Bing Guo; Dongping Shang
Journal:  Onco Targets Ther       Date:  2016-06-22       Impact factor: 4.147

6.  Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Authors:  Simon K B Spohn; Ilias Sachpazidis; Rolf Wiehle; Benedikt Thomann; August Sigle; Peter Bronsert; Juri Ruf; Matthias Benndorf; Nils H Nicolay; Tanja Sprave; Anca L Grosu; Dimos Baltas; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.